Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021051 (
immunodeficiency
)
71,517
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bruton's tyrosine kinase
is intimately involved in signal transduction pathways regulating survival, activation, proliferation, and differentiation of B lineage lymphoid cells. Mutations in the human btk gene are the cause of X-linked agammaglobulinemia, a male
immune deficiency disorder
characterized by a lack of mature, immunoglobulin-producing B lymphocytes. We have determined the x-ray crystal structure of the
Bruton's tyrosine kinase
kinase domain in its unphosphorylated state to a 2.1 A resolution. A comparison with the structures of other tyrosine kinases and a possible mechanism of activation unique to
Bruton's tyrosine kinase
are provided.
...
PMID:Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. 1152 64
Bruton's tyrosine kinase
(
Btk
) is required for human and mouse B cell development.
Btk
deficiency causes X-linked agammaglobulinemia (XLA) in humans and X-linked
immunodeficiency
in mice. Unlike Src proteins,
Btk
lacks a negative regulatory domain at the COOH terminus and may rely on cytoplasmic
Btk
-binding proteins to regulates its kinase activity by trans-inhibitor mechanisms. Consistent with this possibility, IBtk, which we identified as an inhibitor of
Btk
, bound to the PH domain of
Btk
. IBtk downregulated
Btk
kinase activity,
Btk
-mediated calcium mobilization and nuclear factor-kappaB-driven transcription. These results define a potential mechanism for the regulation of
Btk
function in B cells.
...
PMID:Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. 1157 40
Bright, or B cell regulator of immunoglobulin heavy chain transcription, is a B lymphocyte-specific protein first discovered for its ability to increase immunoglobulin transcription three- to sevenfold in antigen-activated B cells. It interacts with DNA through an ARID, or A/T-rich interaction domain, and is the only member of a previously undescribed family of DNA-binding proteins for which target genes have been identified. The mechanism(s) by which Bright facilitates transcription are unknown. Several proteins that associate with Bright may shed light upon its function. These include the nuclear matrix proteins sp100 and LYSp100B, and suggest that Bright may affect chromatin configuration and nuclear sublocalization. Furthermore,
Bruton's tyrosine kinase
is required for Bright binding activity, suggesting links between Bright, cell signaling cascades, and X-linked
immunodeficiency
disease.
...
PMID:The transcription factor, Bright, and immunoglobulin heavy chain expression. 1159 53
Mutations in
Bruton's tyrosine kinase
(
Btk
) result in X-linked agammaglobulinemia (XLA) in humans and X-linked
immunodeficiency
(xid) in mice. While targeted disruption of the protein kinase C-beta (PKCbeta) gene in mice results in an
immunodeficiency
similar to xid, the overall tyrosine phosphorylation of
Btk
is significantly enhanced in PKCbeta-deficient B cells. We provide direct evidence that PKCbeta acts as a feedback loop inhibitor of
Btk
activation. Inhibition of PKCbeta results in a dramatic increase in B-cell receptor (BCR)-mediated Ca2+ signaling. We identified a highly conserved PKCbeta serine phosphorylation site in a short linker within the Tec homology domain of
Btk
. Mutation of this phosphorylation site led to enhanced tyrosine phosphorylation and membrane association of
Btk
, and augmented BCR and FcepsilonRI-mediated signaling in B and mast cells, respectively. These findings provide a novel mechanism whereby reversible translocation of
Btk
/Tec kinases regulates the threshold for immunoreceptor signaling and thereby modulates lymphocyte activation.
...
PMID:PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. 1159 12
Bruton's tyrosine kinase
(
Btk
), a member of the Tec family of protein-tyrosine kinases, has been shown to be crucial for B cell development, differentiation, and signaling. Mutations in the
Btk
gene lead to X-linked agammaglobulinemia in humans and X-linked
immunodeficiency
in mice. Using a co-transfection approach, we present evidence here that
Btk
interacts physically with caveolin-1, a 22-kDa integral membrane protein, which is the principal structural and regulatory component of caveolae membranes. In addition, we found that native Bmx, another member of the Tec family kinases, is associated with endogenous caveolin-1 in primary human umbilical vein endothelial cells. Second, in transient transfection assays, expression of caveolin-1 leads to a substantial reduction in the in vivo tyrosine phosphorylation of both
Btk
and its constitutively active form, E41K. Furthermore, a caveolin-1 scaffolding peptide (amino acids 82--101) functionally suppressed the autokinase activity of purified recombinant
Btk
protein. Third, we demonstrate that mouse splenic B-lymphocytes express substantial amounts of caveolin-1. Interestingly, caveolin-1 was found to be constitutively phosphorylated on tyrosine 14 in these cells. The expression of caveolin-1 in B-lymphocytes and its interaction with
Btk
may have implications not only for B cell activation and signaling, but also for antigen presentation.
...
PMID:Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx. 1175 85
X-linked agammaglobulinemia (XLA) is one of the most frequent inherited
immunodeficiency
diseases in man and is characterized by an almost complete arrest of B cell differentiation at the pre-B cell stage. The gene defective in XLA encodes the cytoplasmic signaling molecule
Bruton's tyrosine kinase
(
Btk
). Next to the CBA/N strain of mice, carrying a single amino acid substitution mutation in the
Btk
gene, which results in the X-linked
immunodeficiency
(xid) phenotype, additional mouse models have been developed to study the role of
Btk
in vivo. This review discusses the analyses of
Btk
null-mutants, obtained by gene targeting in embryonic stem cells, and transgenic mice that express wild-type or mutated forms of the
Btk
gene. These studies provided information on the function of
Btk
at several important checkpoints throughout B cell development. Analyses of the mouse models indicated that
Btk
is not essential for pre-B cell receptor signaling in the mouse. By contrast,
Btk
-mediated B cell receptor signaling appears to be required for the survival of immature B cells in the bone marrow, that have performed a successful immunoglobulin (Ig) L chain locus rearrangement, resulting in the expression of a non-autoreactive Ig on the membrane.
Btk
is also shown to be involved in signaling pathways that govern the development of peripheral B cells, including follicular entry, follicular maturation and plasma cell differentiation.
...
PMID:Role of Bruton's tyrosine kinase in B cell development. 1178 67
The molecular basis of common variable
immunodeficiency
(CVID) is unknown. To assess humoral immunity in CVID, we selected 24 patients with early or late onset of disease. X-linked agammaglobulinemia (XLA), X-linked hyper-IgM syndrome (XHIM), and non-XHIM were excluded based on clinical phenotype, assessment of the immune response, presence of
Bruton's tyrosine kinase
(
Btk
) in monocytes or platelets, and normal expression of CD40 ligand by activated T cells. The number of circulating B cells was within the normal range or reduced. IgD(-) CD27(+) memory B cells were markedly reduced or absent in all 24 patients and IgD(+) CD27(+) B cells were diminished in 8 patients. Circulating B cells from all 6 patients examined, including CVID patients with IgD(+) CD27(+) cells, failed to undergo somatic hypermutation in immunoglobulin-variable (V)-region genes, similar to cord blood B cells. B cells from CVID patients produced IgM and IgG, but not IgA upon the engagement of Ig receptor and CD40 in the presence of IL-2 and IL-10. B cells from all but 5 patients secreted IgE when stimulated by CD40 crosslinking in the presence of IL-4. The observation of defective memory B cells with abnormal cell marker expression and function demonstrates that naive CVID B cells including those expressing IgD(+) CD27(+), in analogy to cord blood and hyper-IgM syndrome B cells, may be responsible for their failure to differentiate into plasma cells and to produce high-affinity antibodies of different isotypes.
...
PMID:Absence of memory B cells in patients with common variable immunodeficiency. 1198 83
CD19 and
Bruton's tyrosine kinase
(
Btk
) may function along common signaling pathways in regulating intrinsic and B cell Ag receptor (BCR)-induced signals. To identify physical and functional interactions between CD19 and
Btk
, a CD19-negative variant of the A20 B cell line was isolated, and CD19-deficient (CD19(-/-)) and CD19-overexpressing mice with the X-linked immunodeficient (Xid;
Btk
) mutation were generated. In A20 cells,
Btk
physically associated with CD19 following BCR engagement. CD19 and
Btk
interactions were not required for initial
Btk
phosphorylation, but CD19 expression maintained
Btk
in an activated state following BCR engagement. In primary B cells, CD19 signaling also required downstream
Btk
function since CD19-induced intracellular Ca(2+) ([Ca(2+)](i)) responses were modest in Xid B cells. In addition, CD19 overexpression did not normalize the Xid phenotype and most phenotypic and functional hallmarks of CD19 overexpression were not evident in these mice. However, CD19 and
Btk
also regulate independent signaling pathways since their combined loss had additive inhibitory effects on BCR-induced [Ca(2+)](i) responses and CD19 deficiency induced a severe
immunodeficiency
in Xid mice. Thus, CD19 expression amplifies or prolongs
Btk
-mediated signaling, rather than serving as a required agent for
Btk
activation. Consistent with this, phosphatidylinositol 3-monophosphate kinase and Akt activation were normal in CD19(-/-) B cells following IgM engagement, although their kinetics of activation was altered. Thus, these biochemical and compound gene dosage studies indicate that
Btk
activation and [Ca(2+)](i) responses following BCR engagement are regulated through multiple pathways, including a CD19/Src family kinase-dependent pathway that promotes the longevity of
Btk
signaling.
...
PMID:Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction. 1202 40
To evaluate whether the diagnosis of X-linked agammaglobulinemia (XLA) is being made in a timely fashion, the clinical findings leading to the diagnosis of XLA were determined in 82 patients with proven mutations in
Bruton's tyrosine kinase
(60 patients with sporadic disease and 22 patients with familial disease). Recurrent otitis was seen in almost all of the patients with sporadic XLA who were older than 12 months at the time of diagnosis. However, fewer than 10% of patients were evaluated for
immunodeficiency
before they were hospitalized for infection; 38% of patients were hospitalized more than once before diagnosis. We conclude that the majority of patients with XLA were recognized to have
immunodeficiency
during or shortly after their first hospitalization for infection. Most of the patients had a history of recurrent otitis at the time of diagnosis, which when combined with the physical finding of markedly decreased or absent tonsils and cervical lymph nodes, could have alerted physicians to the diagnosis of XLA.
...
PMID:Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. 1237 99
Disruption of
Bruton's tyrosine kinase
(
BTK
) function leads to x-linked
immunodeficiency
(xid) in mice.
BTK
-deficient (btk(-/-)) B cells are defective for survival. Prior studies show that
BTK
is required for the induction of Bcl-x(L) following B cell antigen receptor (BCR) engagement. However, the mechanism underlying Bcl-x(L) induction in response to BCR ligation remains unresolved. We now demonstrate that
BTK
regulates bcl-x expression by transcriptional control in response to BCR engagement.
BTK
targets nuclear factor-kappaB (NF-kappaB) to activate the bcl-x promoter via a phospholipase C-gamma2 (PLC-gamma2)-dependent mechanism. Perturbation of the
BTK
/PLC-gamma2/NF-kappaB signaling axis likely contributes to the defective expression of bcl-x and compromised survival of xid B cells.
...
PMID:Bruton's tyrosine kinase targets NF-kappaB to the bcl-x promoter via a mechanism involving phospholipase C-gamma2 following B cell antigen receptor engagement. 1245 62
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>